- Home
- PLX vs ABOS Comparison
PLX vs ABOS Comparison
Compare PLX & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PLX | ABOS |
|---|---|---|
| Founded | 1993 | 1996 |
| Country | United States | United States |
| Employees | 226 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 159.5M | 182.0M |
| IPO Year | 1996 | 2021 |
Fundamental Metrics
Financial Performance| Metric | PLX | ABOS |
|---|---|---|
| Price | $1.98 | $2.18 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $12.00 | $8.00 |
| AVG Volume (30 Days) | ★ 767.9K | 270.2K |
| Earning Date | 05-12-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.22 | N/A |
| Revenue | ★ $52,744,000.00 | N/A |
| Revenue This Year | $36.81 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $9.07 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.34 | $0.99 |
| 52 Week High | $3.19 | $3.60 |
Technical Indicators
Market Signals| Indicator | PLX | ABOS |
|---|---|---|
| Relative Strength Index (RSI) | 36.37 | 33.36 |
| Support Level | $1.87 | $1.23 |
| Resistance Level | $2.15 | $2.42 |
| Average True Range (ATR) | 0.11 | 0.13 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 31.40 | 2.02 |
Price Performance
Historical ComparisonAbout PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers. The product pipelines include: ALTITUDE-AD; and INTERCEPT-AD.